Enzymatica: Q2 2023 initial take - Redeye

Redeye provides an initial take on Enzymatica’s Q2 2023 report. Sales during the quarter amounted to SEK8.8m (SEK9.6m) compared to our sales estimate of SEK7.1m. Moreover, EBIT came in at SEK-11.2m (SEK-15.9m), and the cash position at the end of the period amounted to SEK29.1m. Overall, the results were in line with our expectations. We will provide a more in-depth update shortly; however, we do not expect to make any major estimates or valuation changes.

Länk till analysen i sin helhet: https://www.redeye.se/research/922960/enzymatica-q2-2023-initial-take?utm_source=finwire&utm_medium=RSS